ArticleMedicine2026
Lupus erythematosus-specific bullous lesions: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleLupus erythematosus-specific bullous lesions (LE-SBL) is a rare cutaneous phenotype of lupus erythematosus, characterized by tense vesicles or bullae that readily mimic other primary bullous disorders. PATIENT CONCERNS: A 79-year-old man presented with an abrupt onset of extensive tense bullae and erosions on the trunk, extremities, and oral mucosa, accompanied by pruritus and pain; no systemic involvement was detected. DIAGNOSES: Histopathology revealed a subepidermal blister with a predominantly lymphocytic infiltrate. Enzyme-linked immunosorbent assay for anti-type VII collagen antibodies was negative. Serologic studies demonstrated a markedly elevated anti-Ro-52 antibody titer (>500 U/mL) and a weakly positive antinuclear antibody (1:80, nucleolar pattern). A diagnosis of LE-SBL was established.
interventionsIntravenous methylprednisolone combined with oral hydroxychloroquine was administered, supplemented by symptomatic care. OUTCOMES: After systematic treatment, the patient's blisters subsided and the eroded areas healed, with no new skin lesions observed during the follow-up period. LESSONS: This study provides a comprehensive analysis of LE-SBL and further refines current understanding of the disease. Integration of histopathology, direct/indirect immunofluorescence, and serologic testing is essential to distinguish this entity from other bullous dermatoses. Early institution of glucocorticoids plus hydroxychloroquine achieves rapid disease control. This report offers an important reference for clinicians encountering similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.